Thermochemoterapy in adjuvan treatment of primary high risk non-muscle-invasive bladder cancers

According to European Organization for Research and Treatment of Cancer (EORTC) identified there is a general concensus to use intravesical BCG for non-muscle-invasive bladder cancer. In our study, we aimed to present results of intravesical mytomicin thermo-chemoterapy in patients with primary high risk. We applied adjuvant thermo-chemoterapy to total 26 patients with primary high risk who were performed transurethral resection-bladder between November 2011 and November 2014. Applications was performed via Synergo® device 6 weeks following induction was performed 1 time per week and 1 time per month maintenance intravesical as 6 months. The administrations were applied monthly intervals for 6 months after one intravesical instillation per week for 6 weeks. The following cystocopies should be repeated every 3 months for a period of 2 years, every 4 months in the third year. Recurrent bladder tumor occurred in 3 of the 26 patients who included in this study in follow up of 36 months. 26 patients ( males 24 and 2 females) with a mean age of 62,4 (51-78). In two of these patients developed reccurent bladder tumor (TaGII), other patient developed recurrence in the ureter (TaGII). We found three-year recurrence-free survival rate was about 88,4 %. Radiofrequency thermo-chemoterapy has shown to be promising alternative method for patients which primary high risk and/or refracting BCG at intravesical therapy, especially in the last decade. Our data hasbeen found similar to other studies on this subject. It should be supported with prospective randomized trialsand larger patients series.